Advancing innovation in accelerated cancer diagnosis supports research collaborations to develop and validate diagnostic technologies for earlier cancer detection and future NHS adoption.
The application deadline has been extended from 28 October to 4 November 2026 at 11:00am. Interview invitations will now be sent on 11 December 2026 instead of 7 December.
This grant funds early-stage, highly innovative technology development projects to improve cancer research or clinical care, focusing on proof-of-concept studies with high potential impact in cancer-related fields.
UKRI Translation: MRC Impact Acceleration Awards support academic researchers to test a high-risk development step for medical products or interventions, generating evidence to guide progress towards patient benefit.
Acceleration Initiative Award supports researchers pursuing translational and preclinical pediatric cancer treatment research to overcome development barriers and reach clinical trials within three years.
Cancer Research UK's CDD supports the development of novel cancer agents from preclinical stages to early clinical trials with expert resources, not monetary funding.
Biology to Prevention Award supports research teams studying biological mechanisms of cancer development and risk to develop precision approaches to primary prevention and ultimately reduce cancer incidence.